

company announcement

Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 28 April 2017

Bagsværd, Denmark, 28 April 2017 – In accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred.

Referring to Company Announcement no 29/2017 dated 21 April 2017, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 28 April 2017.

	Number of shares (nominal value DKK 0.20)	Nominal value (DKK)	Number of votes
A shares	537,436,000	107,487,200	107,487,200,000
B shares	1,962,564,000	392,512,800	39,251,280,000

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#)

Further information

Media:

Anne Margrethe Hauge	+45 3079 3450	amhg@novonordisk.com
----------------------	---------------	--

Investors:

Peter Hugrefte Ankersen	+45 3075 9085	phak@novonordisk.com
Hanna Ögren	+45 3079 8519	haoe@novonordisk.com
Anders Mikkelsen	+45 3079 4461	armk@novonordisk.com
Kasper Veje (US)	+1 609 235 8567	kpvj@novonordisk.com